Chemistry:Meclonazepam

From HandWiki
Short description: Chemical compound
Meclonazepam
Meclonazepam structure.svg
Clinical data
ATC code
  • none
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC16H12ClN3O3
Molar mass329.74 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Meclonazepam[1] ((S)-3-methylclonazepam) was discovered by a team at Hoffmann-La Roche in the 1970s and is a drug which is a benzodiazepine derivative similar in structure to clonazepam.[2] It has sedative and anxiolytic actions like those of other benzodiazepines,[3] and also has anti-parasitic effects against the parasitic worm Schistosoma mansoni.[4]

Meclonazepam was never used as medicine and instead appeared online as a designer drug.[5][6][7][8]

Legal Issues

United Kingdom

In the UK, meclonazepam has been classified as a Class C drug by the May 2017 amendment to The Misuse of Drugs Act 1971 along with several other designer benzodiazepine drugs.[9]

See also

References

  1. Szente A, "Benzodiazepine derivatives", US patent 4031078, issued 21 June 1977, assigned to Hoffmann La Roche Inc.
  2. The Lundbeck Institute. "Meclonazepam". Psychotropics. Lundbeck. http://www.psychotropics.dk/moleculeView/default.aspx?ID=1426&Catalogtype=A&ChapterID=1&Thissortorder=23. 
  3. "Initial study of methylclonazepam in generalized anxiety disorder. Evidence for greater power in the cross-over design". Psychopharmacology 87 (2): 130–135. 1985. doi:10.1007/bf00431795. PMID 3931136. https://orbi.uliege.be/bitstream/2268/259489/1/Ansseau1985_Article_InitialStudyOfMethylclonazepam.pdf. 
  4. "Central effects in man of the novel schistosomicidal benzodiazepine meclonazepam". European Journal of Clinical Pharmacology 29 (1): 105–108. 1985. doi:10.1007/bf00547377. PMID 4054198. 
  5. "Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes". Analytical and Bioanalytical Chemistry 408 (13): 3571–3591. May 2016. doi:10.1007/s00216-016-9439-6. PMID 27071765. 
  6. "Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays". Drug Testing and Analysis 9 (4): 640–645. April 2017. doi:10.1002/dta.2003. PMID 27366870. 
  7. "Experimental versus theoretical log D7.4 , pKa and plasma protein binding values for benzodiazepines appearing as new psychoactive substances". Drug Testing and Analysis 10 (8): 1258–1269. March 2018. doi:10.1002/dta.2387. PMID 29582576. https://rke.abertay.ac.uk/en/publications/527a634d-decc-4d3a-bdca-08659bb13ed6. 
  8. "The blood-to-plasma ratio and predicted GABAA-binding affinity of designer benzodiazepines". Forensic Toxicology 40 (2): 349–356. July 2022. doi:10.1007/s11419-022-00616-y. PMID 36454409. 
  9. "The Misuse of Drugs Act 1971 (Amendment) Order 2017". http://www.legislation.gov.uk/uksi/2017/634/contents/made. 

Further reading

  • "Experimentally promising antischistosomal drugs: a review of some drug candidates not reaching the clinical use". Parasitology Research 105 (4): 899–906. October 2009. doi:10.1007/s00436-009-1546-2. PMID 19588166.